Edward F Nash
Overview
Explore the profile of Edward F Nash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials
Davies G, Rowbotham N, Smith S, Elliot Z, Gathercole K, Rayner O, et al.
J Cyst Fibros
. 2019 Nov;
19(3):499-502.
PMID: 31735561
In a recent James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF) the top priority clinical research question was: "What are effective ways of simplifying the treatment burden of...
12.
Webb K, Fogarty A, Barrett D, Nash E, Whitehouse J, Smyth A, et al.
J Med Microbiol
. 2019 Nov;
68(12):1823-1828.
PMID: 31671047
is an important respiratory pathogen in cystic fibrosis (CF), which is associated with an accelerated decline in lung function, frequent pulmonary exacerbations and increased mortality. produces intercellular signalling molecules including...
13.
Hoo Z, Coates E, Maguire C, Cantrill H, Shafi N, Nash E, et al.
Eur J Clin Microbiol Infect Dis
. 2018 Aug;
37(11):2219-2222.
PMID: 30121804
No abstract available.
14.
Khan A, Nash E, Whitehouse J, Rashid R
BMJ Open Qual
. 2017 Sep;
6(2):e000020.
PMID: 28959778
Background: The West Midlands Adult Cystic Fibrosis (CF) Centre based at Birmingham Heartlands Hospital provides care for adults with CF in the West Midlands. People with CF are prone to...
15.
Rowbotham N, Smith S, Leighton P, Rayner O, Gathercole K, Elliott Z, et al.
Thorax
. 2017 Aug;
73(4):388-390.
PMID: 28778919
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research should focus on questions which are most important to the CF community. We conducted a James Lind...
16.
Greenwood J, Schwarz C, Sommerwerck U, Nash E, Tamm M, Cao W, et al.
Ther Adv Respir Dis
. 2017 Jun;
11(7):249-260.
PMID: 28614995
Background: This study assessed the ease of use of tobramycin inhalation powder (TIP) administered via T-326 inhaler versus tobramycin inhalation solution (TIS) and colistimethate sodium (COLI), both administered via nebulizers,...
17.
Choyce J, Shaw K, Sitch A, Mistry H, Whitehouse J, Nash E
BMC Pulm Med
. 2017 Jan;
17(1):22.
PMID: 28114922
Background: Home monitoring has the potential to detect early pulmonary exacerbations in people with cystic fibrosis (CF), with consequent improvements in health outcomes and healthcare associated costs. This study aims...
18.
Bryant J, Grogono D, Rodriguez-Rincon D, Everall I, Brown K, Moreno P, et al.
Science
. 2016 Nov;
354(6313):751-757.
PMID: 27846606
Lung infections with Mycobacterium abscessus, a species of multidrug-resistant nontuberculous mycobacteria, are emerging as an important global threat to individuals with cystic fibrosis (CF), in whom M. abscessus accelerates inflammatory...
19.
Barr H, Halliday N, Barrett D, Williams P, Forrester D, Peckham D, et al.
J Cyst Fibros
. 2016 Oct;
16(2):230-238.
PMID: 27773591
Background: Pulmonary P. aeruginosa infection is associated with poor outcomes in cystic fibrosis (CF) and early diagnosis is challenging, particularly in those who are unable to expectorate sputum. Specific P....
20.
Harte J, Golby C, Acosta J, Nash E, Kiraci E, Williams M, et al.
Med Biol Eng Comput
. 2016 Feb;
54(11):1631-1640.
PMID: 26872677
Respiratory disease is the leading cause of death in the UK. Methods for assessing pulmonary function and chest wall movement are essential for accurate diagnosis, as well as monitoring response...